CytomX Therapeutics, Inc.CTMXNASDAQ

Revenue (LTM)

$76M

-44.8% YoY

Net Income (LTM)

$-17M

-154.5% YoY

Free Cash Flow

$-76M

Revenue CAGR (5Y)

+19.5%

—Marginsstable

FCF($0.1B)

Now unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	37	53↑42.5%	101↑90.4%	138↑36.4%	76↓44.8%
Gross Profit	37	53↑42.5%	101↑90.4%	138↑36.4%	76↓44.8%
Operating Income	-116	-101↑12.7%	-6↑93.6%	25↑485.5%	-20↓178.3%
Net Income	-116	-99↑14.3%	-1↑99.4%	32↑5700.9%	-17↓154.5%
EBITDA	-113	-99↑12.7%	-4↑95.6%	27↑721.1%	-18↓168.0%
EPS Diluted	-1.26	-1.48↓17.5%	-0.01↑99.5%	0.38↑5035.1%	-0.15↓139.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	206	194↓5.8%	17↓91.1%	38↑121.6%	13↓66.7%
Total Current Assets	310	237↓23.6%	183↓22.8%	107↓41.3%	144↑34.1%
Total Assets	339	261↓23.1%	202↓22.7%	121↓40.3%	152↑25.7%
Total Current Liabilities	78	153↑96.0%	156↑2.2%	86↓45.0%	47↓45.7%
Total Liabilities	340	347↑2.0%	249↓28.1%	121↓51.5%	53↓56.6%
Total Equity	-0	-86↓18582.1%	-47↑44.7%	-0↑99.0%	99↑21812.3%
Total Debt	22	18↓16.7%	14↓22.6%	9↓32.8%	4↓54.8%
Net Debt	-184	-176↑4.5%	-3↑98.2%	-29↓796.7%	-8↑70.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-119	-111↑6.9%	-56↑49.4%	-86↓53.9%	-76↑12.3%
Capital Expenditure	-2	-2↓8.1%	-1↑51.7%	-0↑63.1%	-0↑29.0%
Free Cash Flow	-121	-113↑6.7%	-57↑49.5%	-87↓52.2%	-76↑12.4%
Stock-Based Comp	13	0	9	8↓10.4%	6↓17.8%
Net Change in Cash	14	-12↓186.9%	-176↓1385.5%	21↑111.9%	-25↓218.6%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance